VGX-3100: Phase II data

A double-blind, international Phase II trial in 143 women with biopsy-proven CIN 2/3 associated with HPV types 16 or 18 showed that 6 mg intramuscular VGX-3100 followed by electroporation with Inovio’s Cellectra device at weeks 0, 4 and 12 met the primary endpoint of a greater proportion of patients with histopathological regression of cervical dysplasia to CIN 1 or no disease at week 36 vs. placebo (49.5% vs. 30.6%, p<0.025). VGX-3100 also met the secondary endpoint of a greater proportion of patients with virological clearance of HPV types 16 or 18 from the cervix in conjunction with histopathological regression of cervical dysplasia to CIN 1 or no disease vs. placebo (40.2% vs. 14.3%, p<0.025). ...